Thursday, 26 February 2026
An expert in Clinical Trials from the University of Nottingham is part of an international team of experts who have come together to enhance clinical trial conduct and reporting.
Paediatric randomised controlled trials provide evidence for patients, families, researchers, clinicians, regulators, funders, policymakers and other interest-holders to inform decisions regarding healthcare interventions and improve outcomes for patients and their families.
The BMJ has teamed up with leading paediatric journals JAMA Pediatrics and The Lancet Child & Adolescent Health to co-publish two papers that will enhance trial conduct and reporting to improve the health of young patients and their families.
The papers provide essential checklist items for researchers to include in clinical trial protocols and reports aimed at enhancing the usefulness, and impact of paediatric randomised controlled trials.
For example, what is the rationale for undertaking the trial in children/adolescents and how will participants’ consent be obtained and their confidentiality respected? How will age or development-related differences in treatment effects be addressed, and what impact will trial participation have on the child/adolescent’s daily life?
The paper authors say this new guidance will strengthen the quality and safety of the paediatric evidence base, improve health outcomes of children and adolescents, and reduce research and resource waste. Importantly, both guidelines were developed in partnership with young people (ages 10-24 years) and family caregivers.
Professor Ed Juszczak, Professor of Clinical Trials and Statistics in Medicine, Nottingham Clinical Trials Unit, is part of the international collaboration that has produced these new reporting guidelines plus associated Explanation and Elaboration papers.
Ed has a long track record in perinatal clinical trials and has led or co-authored several other similar reporting guidelines. His role on the international steering committee included contributing to discussions around the creation of a long list of prospective items, shortlisting, reviewing the results of the Delphi processes, sourcing examples of good reporting, and dissemination.
While there are many guidelines for the reporting of clinical trials, none up until now, have addressed the unique aspects specific to research involving children and young people. These guidelines should lead to clinical trials that are better designed and conducted, and importantly, reported more transparently. Ultimately this will lead to improved care and outcomes for children, young people and their families in the future.”
Story credits
The links to the papers can be found below:
Enhancing the reporting and impact of paediatric randomised trials: CONSORT-Children and Adolescents (CONSORT-C) 2026 extension
https://www.bmj.com/content/392/bmj-2025-085061
Enhancing the reporting and usefulness of paediatric randomised trial protocols: SPIRIT-Children and Adolescents (SPIRIT-C) 2026 extension
https://www.bmj.com/content/392/bmj-2025-085062
CONSORT-C 2026 Explanation and Elaboration: Recommendations for enhancing the reporting and impact of paediatric randomised trials
https://www.bmj.com/content/392/bmj-2025-085063
SPIRIT-C 2026 Explanation and Elaboration: Recommendations for enhancing the reporting and usefulness of paediatric randomised trial protocols
https://www.bmj.com/content/392/bmj-2025-085064
Notes to editors:
About the University of Nottingham
Ranked 97 in the world and 17th in the UK by the QS World University Rankings, the University of Nottingham is a founding member of Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 – the third time it has been given the honour since 2018 – and by the Daily Mail University Guide 2024.
The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.
The university is a major employer and industry partner - locally and globally - and our graduates are the third most targeted by the UK's top employers, according to The Graduate Market in 2024 report by High Fliers Research. Alongside Nottingham Trent University, we lead the Universities for Nottingham initiative, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home. More news…